Company Summary
LeukoVet is developing a peptide-based cancer therapeutic for treatment of canine lymphoma, leukemia, and other immunological diseases. Leukovet’s technology targets activated white blood cells and holds the potential to vastly improve the lives of millions of companion animals while avoiding the toxicity and side-effects associated with conventional chemotherapies. Leukovet believes a cure for blood cancers is in reach and is focused on bringing a new therapeutic option to companion animals in need.